Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Nuciforo

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 15, 2003
Büschke-Lowenstein tumour in pregnancyG Garozzo, G Nuciforo, C M Rocchi, et al.
Cancer Research|February 19, 2008
The differential role of L1 in ovarian carcinoma and normal ovarian surface epitheliumSilvia Zecchini, Marco Bianchi, Nicoletta Colombo, et al.
Oncology Letters|June 29, 2012
Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatmentA Ieni, G Giuffrè, S Lanzafame, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) statusP G Nuciforo, C Aura, E Holmes, et al.
Oncotarget|October 10, 2015
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patientsLeticia De Mattos-Arruda, Giulia Bottai, Paolo G Nuciforo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Molecular Cancer Therapeutics|September 5, 2021
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine PathwayMelanie Wurm, Otmar Schaaf, Katharina Reutner, et al.
Oncotarget|July 28, 2016
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancerMarta Hergueta-Redondo, David Sarrio, Ángela Molina-Crespo, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
The EMBO Journal|August 22, 2025
Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancerJessica Karta, Marianne Meyers, Fabien Rodriguez, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
European Journal of Obstetrics, Gynecology, and Reproductive Biology|October 15, 2003
Büschke-Lowenstein tumour in pregnancyG Garozzo, G Nuciforo, C M Rocchi, et al.
Cancer Research|February 19, 2008
The differential role of L1 in ovarian carcinoma and normal ovarian surface epitheliumSilvia Zecchini, Marco Bianchi, Nicoletta Colombo, et al.
Oncology Letters|June 29, 2012
Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatmentA Ieni, G Giuffrè, S Lanzafame, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) statusP G Nuciforo, C Aura, E Holmes, et al.
Oncotarget|October 10, 2015
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patientsLeticia De Mattos-Arruda, Giulia Bottai, Paolo G Nuciforo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2021
Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast CancerZhen Shi, Julia Wulfkuhle, Malgorzata Nowicka, et al.
Molecular Cancer Therapeutics|September 5, 2021
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine PathwayMelanie Wurm, Otmar Schaaf, Katharina Reutner, et al.
Oncotarget|July 28, 2016
Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancerMarta Hergueta-Redondo, David Sarrio, Ángela Molina-Crespo, et al.
NPJ Genomic Medicine|May 29, 2024
Analysis of cell free DNA to predict outcome to bevacizumab therapy in colorectal cancer patientsTom Venken, Ian S Miller, Ingrid Arijs, et al.
The EMBO Journal|August 22, 2025
Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancerJessica Karta, Marianne Meyers, Fabien Rodriguez, et al.
Pageof 4